1. Home
  2. XGN vs CINGW Comparison

XGN vs CINGW Comparison

Compare XGN & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XGN
  • CINGW
  • Stock Information
  • Founded
  • XGN 2002
  • CINGW N/A
  • Country
  • XGN United States
  • CINGW United States
  • Employees
  • XGN N/A
  • CINGW 13
  • Industry
  • XGN Medical Specialities
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • XGN Health Care
  • CINGW Health Care
  • Exchange
  • XGN Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • XGN N/A
  • CINGW N/A
  • IPO Year
  • XGN 2019
  • CINGW 2021
  • Fundamental
  • Price
  • XGN $5.85
  • CINGW $0.03
  • Analyst Decision
  • XGN Strong Buy
  • CINGW
  • Analyst Count
  • XGN 2
  • CINGW 0
  • Target Price
  • XGN $7.50
  • CINGW N/A
  • AVG Volume (30 Days)
  • XGN 265.8K
  • CINGW N/A
  • Earning Date
  • XGN 05-05-2025
  • CINGW N/A
  • Dividend Yield
  • XGN N/A
  • CINGW N/A
  • EPS Growth
  • XGN N/A
  • CINGW N/A
  • EPS
  • XGN N/A
  • CINGW N/A
  • Revenue
  • XGN $56,724,000.00
  • CINGW N/A
  • Revenue This Year
  • XGN $17.16
  • CINGW N/A
  • Revenue Next Year
  • XGN $16.10
  • CINGW N/A
  • P/E Ratio
  • XGN N/A
  • CINGW N/A
  • Revenue Growth
  • XGN 1.78
  • CINGW N/A
  • 52 Week Low
  • XGN $1.32
  • CINGW N/A
  • 52 Week High
  • XGN $6.34
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • XGN 58.45
  • CINGW N/A
  • Support Level
  • XGN $5.87
  • CINGW N/A
  • Resistance Level
  • XGN $7.20
  • CINGW N/A
  • Average True Range (ATR)
  • XGN 0.66
  • CINGW 0.00
  • MACD
  • XGN -0.01
  • CINGW 0.00
  • Stochastic Oscillator
  • XGN 58.52
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: